Galecto (Galecto) Price-to-Tangible-Book : 0.65 (As of May. 14, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Galecto Price-to-Tangible-Book?

As of today (2024-05-14), Galecto's share price is $0.6801. Galecto's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $1.04. Hence, Galecto's Price to Tangible Book Ratio of today is 0.65.

The historical rank and industry rank for Galecto's Price-to-Tangible-Book or its related term are showing as below:

GLTO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.48 Med: 0.68 Max: 1.91
Current: 0.65

During the past 6 years, Galecto's highest Price to Tangible Book Ratio was 1.91. The lowest was 0.48. And the median was 0.68.

GLTO's Price-to-Tangible-Book is ranked better than
90.9% of 1220 companies
in the Biotechnology industry
Industry Median: 2.71 vs GLTO: 0.65

A closely related ratio is called PB Ratio. As of today, Galecto's share price is $0.6801. Galecto's Book Value per Sharefor the quarter that ended in Mar. 2024 was $1.04. Hence, Galecto's P/B Ratio of today is 0.65.

Galecto Price-to-Tangible-Book Historical Data

The historical data trend for Galecto's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galecto Price-to-Tangible-Book Chart

Galecto Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

1.91

0.65

0.48

0.60

Galecto Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Price-to-Tangible-Book	Get a 7-Day Free Trial															1.01	1.56	0.52	0.60	0.75

Competitive Comparison of Galecto's Price-to-Tangible-Book

For the Biotechnology subindustry, Galecto's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galecto's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galecto's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Galecto's Price-to-Tangible-Book falls into.

Galecto Price-to-Tangible-Book Calculation

Galecto's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Mar. 2024 )
	=	0.6801	/	1.039
	=	0.65

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Galecto Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Galecto's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Galecto (Galecto) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galecto Inc (NAS:GLTO) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.galecto.com

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis-related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Executives

Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Bertil Lindmark	officer: Chief Medical Officer	C/O GALECTO, INC., OLE MAALOES VEJ 3, COPENHAGEN N G7 DK-2200
Hans T. Schambye	director, officer: Chief Executive Officer	C/O GALECTO, INC., OLE MAALOES VEJ 3, COPENHAGEN N G7 DK-2200
Stephanie Oestreich	officer: Chief Business Officer	75 STATE STREET, SUITE 100, BOSTON MA 02109
Jonathan Freve	officer: Chief Financial Officer	C/O SPRING BANK PHARMACEUTICALS, INC., 113 CEDAR STREET, STE S-7, MILFORD MA 01757
Garrett Winslow	officer: General Counsel	35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748
Anne Prener	director	C/O RUBIUS THERAPEUTICS, 399 BINNEY STREET SUITE 300, CAMBRIDGE MA 02139
Dallas Jayson Donald Alexander	director	AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Chau Quang Khuong	director, 10 percent owner	C/O ORBIMED ADVISORS, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Stephan Christgau	director	C/O CASTLE & MORGAN HOLDINGS, INC., 425 MARKET STREET, SUITE 2230, SAN FRANCISCO CA 94105
Soren Moller	director	C/O NOVO HOLDINGS A/S, TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Anders Pedersen	officer: Chief Operating Officer	C/O GALECTO, INC., OLE MAALOES VEJ 3, COPENHAGEN N G7 DK-2200
Orbimed Advisors Israel Ii Ltd	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Israel Gp Ii, L.p.	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022